Click here - Coronavirus Update - Important Announcement

Research Center

Research Center

Ortho Illinois has long held a commitment to continuing medical education and providing university-level care.  In 2006, it was a natural next step to formalize a program that allows our physicians to participate in the process that contributes to medical research and makes revolutionary new products and treatments possible.

Be a part of our clinical studies:

Studies Currently Active and Enrolling

If interested, please call the Ortho Illinois Research Department at 815-847-7078.

ROTATOR CUFF TEAR

  • Physician:  Scott Trenhaile, MD
  • Description:  Retear rates of medium to large rotator cuff tears in patients who received surgical treatment only as compared to patients who received surgical treatment with Regeneten.
  • Contact:  Sean Kampe, 815-381-7457

SUBCHONDROPLASTY OF THE HIP

  • Physician:  Geoffrey Van Thiel, MD
  • Description:  Post-market clinical outcomes study to collect data on the short- and long-term outcomes for subjects who are undergoing or have undergone the Subchondroplasty® (SCP®) Procedure in the hip in a standard clinical setting.  Outcomes to be assessed include medication usage, pain, function, activity levels and patient satisfaction.
  • Contact:  Sean Kampe, 815-381-7457

SYMPTOMATIC NEUROMA/MORTON’S NEUROMA

  • Physician:  Kelly John, DPM, MHA
  • Description:  A multicenter, prospective, randomized and subject blinded comparative study of axoguard nerve cap and neuectomy for the treatment of symptomatic neuroma and prevention of recurrent end-neuroma pain.
  • Contact:  Sean Kampe, 815-381-7457

CARTILAGE REPAIR OF THE KNEE

  • Physician:  Geoffrey Van Thiel, MD
  • Description:  A prospective, randomized, active treatment-controlled, evaluator-blinded (radiologist and physician evaluator) multicenter study to establish the superiority of a hyaluronan-based scaffold (Hyalofast®) with autologous bone marrow aspirate concentrate (BMAC) in the treatment of articular knee cartilage defect lesions in comparison to control (microfracture treatment).
  • Contact:  Sean Kampe, 185-381-7457

RHEUMATOID ARTHRITIS STUDIES

  • Physician:  Richard Olson, MD
  • Description:  Collect and document use patterns, effectiveness, and safety of all treatments currently used in the management of rheumatoid arthritis which will be maintained in a national database, the Consortium of Rheumatology Researchers of North America (CORRONA), for purposes related to drug safety, clinical outcomes and market research.
  • Contact:  Paige Lamb, 815-484-6942

PSORIATIC ARTHRITIS STUDIES:

  • Physician:  Saad Tariq, MD
  • Description:  The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderatly to severely active psoriatic arthritis (PsA).
  • Contact:  Heather Hackman, 815-381-7468

OSTEOARTHRITIS OF THE KNEE:

  • Physician:  Geoffrey Van Thiel, MD
  • Description:  This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection.  This study will utilize radiographs and patient reported outcomes (PROs) to evaluate the safety and efficacy of lorecivivint.
  • Contact:  Paige Lamb, 815-484-6942

 

  • Physician:  Geoffrey Van Thiel, MD
  • Description:  This study is conducted in male and female patients between>40 and 85 years of age with severe osteoarthritis of the knee.  Approximately 1034 patients with severe osteoarthritis of the knee randomized 1 to 1 treatment group (1:1) will receive a single intra-injection of 4 milliliter (mL) of Ampion or saline.
  • Contact:  Heather Hackman, 815-381-7468

UNILATERAL KNEE REPLACEMENT

  • Physician:  Victor Antonacci, MD
  • Description:  This clinical study will evaluate the early to midterm safety and performance of the JOURNEY II UKS in patients with non-inflammatory degenerative joint disease of the knee requiring lateral or medial knee compartment replacement.  Clinical, radiographic, health economic and safety outcomes will be evaluated.
  • Contact:  Heather Hackman, 815-381-7468

SYSTEMIC ERYTHEMA LUPUS STUDIES

  • Physician: Richard Olson, MD
  • Description:  The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
  • Contact: Paige Lamb, 815-484-6942

 

Upcoming studies:

 

 


About Clinical Research:

Clinical research studies are biomedical or health-related studies that involve patients with a targeted diagnosis. Depending on the specific study, there are usually 50-100 sites nationally or internationally participating in a particular study. Sites are carefully selected based on state-of-the-art diagnostic and facility criteria and by the commitment demonstrated by the physicians involved in top quality patient care.

By participating in national and international clinical research studies at the Phase II-IV levels, Ortho Illinois physicians have access to new treatment options for patients on a local level who have not experienced improvement through other treatments.

Currently, Ortho Illinois has executed over 80 clinical research and post market studies. We are proud to participate in the first-in-class drug studies for the treatment of rheumatoid arthritis, notably Xejanz® and Otezla®.  We seek advanced medical device studies including biodegradable materials or using the body’s own stem cells to heal joint damage.   By gaining years’ of experience using cutting edge technologies, our physicians already have the expertise you desire once a new drug or device is approved by the FDA.

In addition to expanding physicians’ experience and knowledge, being in a clinical trial offers great benefits to patients.  Study participants gain access to new research treatments before FDA approval or availability, receive more services, are assessed more frequently, and have a more active role in their health care.  Participating in a research study offers financial as well as health benefits, especially for those patients with high co-pays or who do not have healthcare coverage.  All laboratory, medication, and physician costs specific to the study are covered for the patient participant by the company conducting the study.

For further information about research studies contact:

Lisa Foti, MS, Director of Research at 815-847-7078.

Paige Lamb, BS, RN, Clinical Research Nurse Coordinator, at 815-484-6942

Sean Kampe, MS,  Clinical Research Coordinator, at 815-381-7457

Heather Hackman, ROT, Clinical Research Coordinator, at 815-381-7468